REGENXBIO aligns with FDA on Navsunli path, shares surge in Nasdaq trade
22.06.2026 - 19:09:00 | ad-hoc-news.de
By Christina Vogel, Background & Management desk. Reviewed prior to publication on 2026-06-22, 19:07.
REGENXBIO Inc (US75901B1052) announced on June 22 that it has reached alignment with the U.S. Food and Drug Administration on a path forward to resubmit the Biologics License Application for its gene therapy Navsunli in Mucopolysaccharidosis type II. The Nasdaq-listed company reported the FDA is prepared to review existing long-term data under the accelerated approval pathway, while premarket indications show a marked double-digit percentage gain in the shares according to third-party market commentary.
What the FDA alignment means
According to the company’s June 22 press release, the FDA confirmed that no additional clinical studies are required for Navsunli, also known as RGX-121 or clemidsogene lanparvovec, to support a BLA resubmission for accelerated approval in MPS II, or Hunter syndrome. REGENXBIO press release on Navsunli and FDA alignment The agency instead plans to review longer-term data from the existing CAMPSIITE study on an expedited timetable.
REGENXBIO stated that it expects to resubmit the Navsunli BLA in the third quarter of 2026, following a formal Type A meeting with the FDA anticipated in July to settle remaining review details. Company statement on resubmission timing If approved, Navsunli would become the first gene therapy treatment option for patients with MPS II, an ultra-rare, progressive neurodegenerative disease.
Premarket reaction on Nasdaq
Market commentary from GuruFocus and Investing.com indicates that REGENXBIO shares rallied strongly in premarket Nasdaq trading on June 22 after reports that the FDA had agreed to reconsider its prior rejection of Navsunli and to work toward a resubmission via the accelerated approval route. GuruFocus summary of premarket move and FDA reconsideration One report cites premarket gains of around 25 percent, with indicative prices near 9.8 US dollars per share.
Investing.com likewise attributes a double-digit pre-open jump to the FDA’s willingness to reverse its earlier Complete Response Letter on Navsunli, which had weighed heavily on the stock earlier in the year. Investing.com report on Navsunli-driven share reaction The renewed regulatory momentum adds to a share price recovery from a 52-week low around 5.46 dollars noted in recent coverage.
All news and analysis on the REGENXBIO shares
Further company announcements, analyst views and price data on REGENXBIO can be found in the dedicated topic overview and on the Investor Relations site.
The product behind Navsunli
Navsunli is REGENXBIO’s investigational one-time gene therapy for MPS II that uses an AAV9 vector to deliver a functional copy of the iduronate-2-sulfatase gene directly to the central nervous system, with the aim of addressing neurological manifestations of Hunter syndrome. Company pipeline overview for Nav platform programs The therapy is administered via intracisternal or intracerebroventricular injection in clinical studies such as CAMPSIITE.
Where the stock trades today
The REGENXBIO shares (US75901B1052) are listed on the Nasdaq Global Select Market under the ticker RGNX; the most recently cited premarket indication on June 22 shows a level around 9.8 US dollars per share in U.S. trading commentary.
Key data on the REGENXBIO shares
- Company: REGENXBIO Inc.
- ISIN: US75901B1052
- WKN: A2AFWU
- Ticker: RGNX
- Trading venue: Nasdaq
- Price (as of 2026-06-22, 15:30): 9.77 USD
- Market cap: 403.24 million USD (as of 2026-06-22)
- Sector / industry: Biotechnology
- Index membership: none of the major headline indices reported
- Next earnings date: 2026-08-06
This article is for informational purposes only and does not constitute investment advice, an offer, or a solicitation to buy or sell any financial instrument. Historical performance is not a reliable indicator of future results.
